Biodexa Pharmaceuticals (BDRX) Long-Term Debt Repayments (2013 - 2016)
Biodexa Pharmaceuticals (BDRX) posted Long-Term Debt Repayments of -$292157.2 for Q4 2016, down 16.68% sequentially from -$250385.9 in Q4 2015, and down 16.68% YoY from -$350656.4 in Q1 2016.
Biodexa Pharmaceuticals (BDRX) Long-Term Debt Repayments (2013 - 2016) Analysis & Trends
Biodexa Pharmaceuticals has reported Long-Term Debt Repayments for 4 years, with the latest figure at -$292157.2 in Q4 2016.
- Quarterly Long-Term Debt Repayments fell 16.68% year-over-year to -$292157.2 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$1.4 million (changed N/A YoY) and the FY2019 annual result came in at -$736735.6, up 90.52% from the prior year.
- Long-Term Debt Repayments slipped to -$292157.2 in Q4 2016 per BDRX's latest filing, from -$250385.9 in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at -$250385.9 in Q4 2015 and troughed at -$548203.5 in Q4 2014.
- A 4-year average of -$353640.3 and a median of -$307985.9 in 2013 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2014 and 2015: Long-Term Debt Repayments tumbled 69.3% in 2014, then jumped 54.33% in 2015.
- Over 4 years, Long-Term Debt Repayments stood at -$323814.7 in 2013, then tumbled by 69.3% to -$548203.5 in 2014, then soared by 54.33% to -$250385.9 in 2015, then retreated by 16.68% to -$292157.2 in 2016.
- According to Business Quant data, Long-Term Debt Repayments over the past three periods registered -$292157.2, -$250385.9, and -$548203.5 for Q4 2016, Q4 2015, and Q4 2014 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -10.01 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -292,157.23 |
| Dec 31, 2016 | -292,157.23 |
| Dec 31, 2015 | -250,385.94 |
| Dec 31, 2015 | -250,385.94 |
| Dec 31, 2014 | -548,203.48 |
| Dec 31, 2014 | -548,203.48 |
| Dec 31, 2013 | -323,814.65 |
| Dec 31, 2013 | -323,814.65 |